| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1371918 | Bioorganic & Medicinal Chemistry Letters | 2010 | 4 Pages |
An imidazolium salt, 1-mesityl-3-(2-naphthoylmethano)-1H-imidazolium bromide (MNIB), has been investigated for its antitumor properties. In vitro studies demonstrate that MNIB is active against K562, SMMC-7721, EJ, AGZY, HEP-2, A549, HepG2, and Raji tumor cells, and can induce the G1 phase cell cycle arrest and apoptosis in K562 cells. Moreover, administration of MNIB significantly inhibited tumor growth in human non-small lung tumor (A549) xenografts.
Graphical abstractAn imidazolium salt, 1-mesityl-3-(2-naphthoylmethano)-1H-imidazolium bromide (MNIB), has been investigated for its antitumor properties. In vitro studies demonstrate that MNIB is active against K562, SMMC-7721, EJ, AGZY, HEP-2, A549, HepG2, and Raji tumor cells, and can induce the G1 phase cell cycle arrest and apoptosis in K562 cells. Moreover, administration of MNIB significantly inhibited tumor growth in human non-small lung tumor (A549) xenografts.Figure optionsDownload full-size imageDownload as PowerPoint slide
